Novelos Therapeutics is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The company’s lead compound – NOV-002 – is in Phase 2 development for early-stage breast cancer and chemotherapy-resistant ovarian cancer. More importantly, the compound is in Phase 3 development for lung cancer (and being fast-tracked by the FDA) and acts together with chemotherapy as a chemoprotectant and chemopotentiator. In addition, the company’s NOV-205 is in Phase 1b development for chronic hepatitis C non-responders.
For investors looking to discover emerging companies, like Novelos Therapeutics, in the micro-cap and small-cap space, the QualityStocks Daily Newsletter is a one-stop resource. With all of the stock picks available in today’s investment world, selecting and deciding on the right stocks can be tedious and time consuming. At QualityStocks, we collate hundreds of investment newsletters into the one and only QualityStocks Daily, featuring a summary format in which you can view the latest stock picks every day! To sign up for free, visit www.signup.qualitystocks.net.